Scott M. Friedman

Ophthalmology
2202 Lakeland Hills Blvd
Lakeland, FL 33805

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials".

A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials".

Journal: Ophthalmology and therapy
Published: May 12, 2026

Correction: Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.

Correction: Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.

Journal: Ophthalmology and therapy
Published: April 04, 2026

Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.

Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.

Journal: Ophthalmology and therapy
Published: March 27, 2026

Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service.

Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service.

Journal: Ophthalmology
Published: February 28, 2026

Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Retina Network Protocol AN).

Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Retina Network Protocol AN).

Journal: Ophthalmology science
Published: January 28, 2026

Reply.

Reply.

Journal: Ophthalmology. Retina
Published: October 01, 2025

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.

Journal: Ophthalmology and therapy
Published: July 07, 2025

Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration.

Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration.

Journal: Ophthalmology. Retina
Published: March 31, 2025

Anti-VEGF Use for Conditions without US Food and Drug Administration Approval.

Anti-VEGF Use for Conditions without US Food and Drug Administration Approval.

Journal: Ophthalmology. Retina
Published: January 01, 2025

Geographic Atrophy Natural History Versus Treatment: Time to Fovea.

Geographic Atrophy Natural History Versus Treatment: Time to Fovea.

Journal: Ophthalmic surgery, lasers & imaging retina
Published: June 25, 2024

Cost analysis of dropless cataract surgery prophylaxis with intracameral antibiotics and subconjunctival steroids.

Cost analysis of dropless cataract surgery prophylaxis with intracameral antibiotics and subconjunctival steroids.

Journal: Journal of cataract and refractive surgery
Published: February 22, 2024

Reply.

Reply.

Journal: Ophthalmology
Published: June 29, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026